124 related articles for article (PubMed ID: 23839757)
21. Spironolactone for heart failure with preserved ejection fraction.
Efthimiadis GK; Zegkos T; Karvounis H
N Engl J Med; 2014 Jul; 371(2):179-80. PubMed ID: 25006728
[No Abstract] [Full Text] [Related]
22. Spironolactone for heart failure with preserved ejection fraction.
Dalzell JR
N Engl J Med; 2014 Jul; 371(2):179. PubMed ID: 25006727
[No Abstract] [Full Text] [Related]
23. Spironolactone for heart failure with preserved ejection fraction.
Pfeffer MA; Pitt B; McKinlay SM
N Engl J Med; 2014 Jul; 371(2):181-2. PubMed ID: 25006726
[No Abstract] [Full Text] [Related]
24. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
25. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.
Vizzardi E; Sciatti E; Bonadei I; D'Aloia A; Tartière-Kesri L; Tartière JM; Cohen-Solal A; Metra M
Clin Res Cardiol; 2015 Dec; 104(12):1078-87. PubMed ID: 26058790
[TBL] [Abstract][Full Text] [Related]
26. Spironolactone in chronic hemodialysis patients improves cardiac function.
Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
[TBL] [Abstract][Full Text] [Related]
27. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
28. Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
Leung DY
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1250-2. PubMed ID: 22172780
[No Abstract] [Full Text] [Related]
29. Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Reddy YNV; Sundaram V
Eur J Heart Fail; 2022 Sep; 24(9):1569-1572. PubMed ID: 35851716
[No Abstract] [Full Text] [Related]
30. Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
Kelly J; Granger CB
Ann Intern Med; 2014 Oct; 161(8):JC6. PubMed ID: 25329223
[No Abstract] [Full Text] [Related]
31. Acute diastolic mitral regurgitation as a mechanism of left ventricular failure in a patient with normal systolic function.
Mohan JC; Shekhar C; Tomar D; Mohan V
Indian Heart J; 2009; 61(3):301-2. PubMed ID: 20503843
[No Abstract] [Full Text] [Related]
32. Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
Ramaraj R
Am Heart J; 2009 Mar; 157(3):e13; author reply e17. PubMed ID: 19249404
[No Abstract] [Full Text] [Related]
33. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
Vizzardi E; Nodari S; Caretta G; D'Aloia A; Pezzali N; Faden G; Lombardi C; Raddino R; Metra M; Dei Cas L
Am J Med Sci; 2014 Apr; 347(4):271-6. PubMed ID: 24196866
[TBL] [Abstract][Full Text] [Related]
34. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure.
Daniel KR; Wells G; Stewart K; Moore B; Kitzman DW
Congest Heart Fail; 2009; 15(2):68-74. PubMed ID: 19379452
[TBL] [Abstract][Full Text] [Related]
35. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
[TBL] [Abstract][Full Text] [Related]
36. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
Fügedi K
Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
[TBL] [Abstract][Full Text] [Related]
37. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Onarecker C
J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
[TBL] [Abstract][Full Text] [Related]
38. [Are aldosterone antagonists effective in patients with mild to moderate heart failure?].
Rada G; Peña J
Medwave; 2014 Jul; 14(6):e5999. PubMed ID: 25353251
[TBL] [Abstract][Full Text] [Related]
39. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Rossignol P; Zannad F
Circulation; 2015 Jan; 131(1):7-10. PubMed ID: 25406307
[No Abstract] [Full Text] [Related]
40. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
